Hydroxylamine bearing amino acid derivatives as collagenase inhibitors
    3.
    发明授权
    Hydroxylamine bearing amino acid derivatives as collagenase inhibitors 失效
    具有氨基酸衍生物的羟胺作为胶原酶抑制剂

    公开(公告)号:US4996358A

    公开(公告)日:1991-02-26

    申请号:US336264

    申请日:1989-04-11

    摘要: Compounds of the formula ##STR1## wherein A is a group of the formula HN(OH)--CO-- or HCO--N(OH)--; R.sup.1 is a C.sub.2 -C.sub.5 -alkyl; R.sup.2 is the characterizing group of a natural .alpha.-amino acid in which any functional group present may be protected, any amino group present may be acylated and any carboxyl group present may be amidated, with the proviso that R.sup.2 is not hydrogen or methyl; R.sup.3 is hydrogen, amino, hydroxy, mercapto, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.6 -alkylamino, C.sub.1 -C.sub.6 -alkylthio or aryl-(C.sub.1 -C.sub.6 -alkyl), or amino-(C.sub.1 -C.sub.6 -alkyl), hydroxy-(C.sub.1 -C.sub.6 -alkyl), mercapto-(C.sub.1 -C.sub.6 -alkyl) or carboxy-(C.sub.1 -C.sub.6 -alkyl) in which the amino, hydroxy, mercapto or carboxyl group may be protected, the amino group may be acylated or the carboxyl group may be amidated; R.sup.4 is hydrogen or methyl; R.sup.5 is hydrogen or a C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, di(C.sub.1 -C.sub.6 -alkoxy)-methylene, carboxyl, (C.sub.1 -C.sub.6 -alkyl)-carbonyl, (C.sub.1 -C.sub.6 -alkoxy)carbonyl, arylmethoxycarbonyl, (C.sub.1 -C.sub.6 -alkyl)aminocarbonyl or arylaminocarbonyl; and R.sup.6 is hydrogen or methyl; or R.sup.2 and R.sup.4 taken together are a group of the formula --(CH.sub.2).sub.n -- in which n is a number from 4 to 11; or R.sup.4 and R.sup.6 taken together are a trimethylene; and pharmaceutically acceptable salts of those compounds which are acidic or basic are described. The compounds of formula I possess collagenase inhibitory activity and can be used in the control or prevention of degenerative joint diseases.

    摘要翻译: 式(Ⅰ)化合物其中A为式HN(OH)-CO-或HCO-N(OH) - 的基团; R1是C2-C5-烷基; R2是天然α-氨基酸的表征基团,其中存在的任何官能团可以被保护,任何存在的氨基可以被酰化,并且存在的任何羧基可以被酰胺化,条件是R 2不是氢或甲基; R3是氢,氨基,羟基,巯基,C1-C6-烷基,C1-C4-烷氧基,C1-C6-烷基氨基,C1-C6-烷硫基或芳基 - (C1-C6-烷基)或氨基 - (C1- C6烷基),羟基 - (C1-C6-烷基),巯基 - (C1-C6-烷基)或羧基 - (C1-C6-烷基),其中氨基,羟基,巯基或羧基可被保护 氨基可以被酰化或羧基可以酰胺化; R4是氢或甲基; R 5是氢或C 1 -C 6烷基,C 1 -C 6烷氧基-C 1 -C 6烷基,二(C 1 -C 6 - 烷氧基) - 亚甲基,羧基,(C 1 -C 6 - 烷基) - 羰基,(C 1 -C 6 - 烷氧基)羰基,芳基甲氧基羰基,(C 1 -C 6 - 烷基)氨基羰基或芳基氨基羰基; R6为氢或甲基; 或者R 2和R 4一起是式 - (CH 2)n - 的基团,其中n是4至11的数; 或R4和R6一起是三亚甲基; 和描述了那些酸性或碱性化合物的药学上可接受的盐。 式I化合物具有胶原酶抑制活性,可用于控制或预防退行性关节疾病。

    Hydroxamic acid derivatives with tricyclic substitution
    7.
    发明授权
    Hydroxamic acid derivatives with tricyclic substitution 失效
    具有三环取代的羟肟酸衍生物

    公开(公告)号:US5614625A

    公开(公告)日:1997-03-25

    申请号:US417317

    申请日:1995-04-05

    摘要: The invention provides hydroxamic acid derivatives of the general formula ##STR1## wherein R.sup.1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; R.sup.2 represents a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring, which N-heterocyclic ring is attached via the N atom and when it is monocyclic, optionally contains NR.sup.4, O, S, SO or SO.sub.2 as a ring member and/or is optionally substituted on one or more C atoms by hydroxy, lower alkyl, lower alkoxy, oxo, ketalized oxo, amino, mono(lower alkyl)amino, di(lower alkyl)amino, carboxy, lower alkoxycarbonyl, hydroxy-methyl, lower alkoxymethyl, carbamoyl, mono(lower alkyl)-carbamoyl, di(lower alkyl)carbamoyl or hydroxyimino; R.sup.3 represents a 5- or 6-membered N-heterocyclic ring which (a) is attached via the N atom, (b) optionally contains N, O and/or S, SO or SO.sub.2 as an additional ring member, (c) is substituted by oxo on one or both C atoms adjacent to the linking N atom and (d) is optionally benz-fused or optionally substituted on one or more other C atoms by lower alkyl or oxo and/or on any additional N atom(s) by lower alkyl or aryl; R.sup.4 represents hydrogen, lower alkyl, aryl, aralkyl or a protecting group; m stands for 1 or 2 and n stands for 1-4, pharmaceutically acceptable salts thereof, intermediates used in the manufacture thereof, and methods of use therefor. Compounds of formula I are collagenase inhibitors useful in the control or prevention of degenerative joint diseases such as rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis.

    摘要翻译: 本发明提供通式为(I)的异羟肟酸衍生物,其中R 1表示环丙基,环丁基,环戊基或环己基; R2表示饱和的5-至8-元单环或桥连的N-杂环,N-杂环通过N原子连接,当其为单环时,任选地含有作为环成员的NR4,O,S,SO或SO2 羟基,低级烷基,低级烷氧基,氧代,缩酮化的氧代,氨基,单(低级烷基)氨基,二(低级烷基)氨基,羧基,低级烷氧基羰基,羟基 - 甲基 ,低级烷氧基甲基,氨基甲酰基,单(低级烷基) - 氨基甲酰基,二(低级烷基)氨基甲酰基或羟基亚氨基; (a)经由N原子连接的5-或6-元N-杂环,(b)任选地含有N,O和/或S,SO或SO 2作为另外的环成员,(c)是 在与连接的N原子相邻的一个或两个C原子上被氧代取代,(d)任选地被苯并稠合或任选地在一个或多个其它C原子上被低级烷基或氧代和/或任何另外的N原子取代, 由低级烷基或芳基取代; R4表示氢,低级烷基,芳基,芳烷基或保护基; m代表1或2,n代表1-4,其药学上可接受的盐,制备中使用的中间体及其用途。 式I化合物是可用于控制或预防变性关节疾病如类风湿性关节炎和骨关节炎或用于治疗浸润性肿瘤,动脉粥样硬化或多发性硬化的胶原酶抑制剂。

    Differential torque motor
    8.
    发明授权
    Differential torque motor 失效
    差速马达

    公开(公告)号:US5475277A

    公开(公告)日:1995-12-12

    申请号:US95688

    申请日:1993-07-21

    CPC分类号: H02P6/08 H02K21/14 H02K29/03

    摘要: A PM (permanent magnet) motor is described, that uses electromagnetic current to release or pull a PM, which has increased starting torque and a large power output in a small volume. The motor includes phase units (60, FIG. 3 ) each having three electromagnets (46A-46C) and each having two PMs (44A, 44B) of Nd-B-Fe permanent magnet material. At a start position, a PM (44B) of each phase unit is centered between the cores (50B, 50C) of two electromagnets, and there is slight overlap (90, FIG. 6 ) of each of the two core faces (64B, 64C) with the PM face (62A). Each PM face has a longer circumferential length (D) than that (G) of each core face. Each PM face and each core face, has an axial length (E, FIG. 1 ) which is much larger than its circumferential length (D, G). The interface end of each electromagnet coil lies a small distance (K) from the core face.

    摘要翻译: 描述了使用电磁电流来释放或拉动PM的PM(永磁体)电动机,其具有增加的起动转矩和大体积的大功率输出。 电动机包括各自具有三个电磁体(46A-46C)并且各自具有Nd-B-Fe永磁材料的两个PM(44A,44B)的相位单元(60)。 在起始位置,每个相位单元的PM(44B)在两个电磁体的芯(50B,50C)之间居中,并且两个芯面(64B,...)中的每一个的轻微重叠(90,图6) 64C)与PM面(62A)。 每个PM面具有比每个芯面的(G)更长的圆周长度(D)。 每个PM面和每个芯面具有比其圆周长度(D,G)大得多的轴向长度(E,图1)。 每个电磁线圈的接口端与芯面相距较小(K)。